Atriva Therapeutics

Re-purposing MEK inhibitors to treat viral infections including COVID-19 and influenza

placeTubingen, Baden Wurttemberg, Germany calendar_todayFounded 2015 groups13 employees language atriva-therapeutics.com

Registered entities

Innovation

16 patent families (8 granted) — focus: Human necessities; filing pace slowing. Cited 930 times.

YearFilings
20151
20161
20172
20181
20196
20204
20218
202210
20235
20244
20254

Investor mix

6 investors on record; lead investors include Meneldor, HTGF, InSynchrony Ventures.

Investor typeCountShare
Venture capital583%
Private equity117%
Coming soon